rokitamycin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
antibiotics, produced by Streptomyces strains 2398 74014-51-0

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • rokitamycin
  • Propionylleucomycin A5
  • ricamycin
  • Molecular weight: 828.01
  • Formula: C42H69NO15
  • CLOGP: 3.84
  • LIPINSKI: 2
  • HAC: 16
  • HDO: 3
  • TPSA: 206.05
  • ALOGS: -4.13
  • ROTB: 15

Drug dosage:

DoseUnitRoute
0.80 g O

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 2.554 Moderate 0.74
caco2-efflux Caco-2 efflux ratio (BA/AB) 10.691 Moderate 0.74
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 19.011 10^-6 cm/s Moderate 0.74
dh-clint Dog hepatocyte intrinsic clearance 41.400 uL/min/10^6 cells Moderate 0.74
dppb Dog plasma protein binding (% unbound) 18.570 % Moderate 0.74
fcs-ppb Fetal calf serum protein binding (% unbound) 24.450 % Moderate 0.74
herg hERG pIC50 4.573 pIC50 Moderate 0.74
hh-clint Human hepatocyte intrinsic clearance 27.861 uL/min/10^6 cells Moderate 0.74
hlm-clint Human liver microsomal intrinsic clearance 211.349 uL/min/mg protein Moderate 0.74
hppb Human plasma protein binding (% unbound) 18.710 % Moderate 0.74
kinase-safety-class ACVR2B,AXL,BRAF,BTK,CAMK2D,CDK5,CDK9,EIF2AK3,EPHB4,ERBB2,GRK2,ITK,MAPK7,NTRK2,PDK1,PDK2,PDK4,PRKDC,TEK,TGFBR1 20
kinase-selectivity-class MAP2K6 1
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 11.402 Moderate 0.74
mh-clint Mouse hepatocyte intrinsic clearance 61.944 Moderate 0.74
mppb Mouse plasma protein binding (% unbound) 14.810 Moderate 0.74
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 31.623 Moderate 0.74
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pppb Pig plasma protein binding (% unbound) 21.050 % Moderate 0.74
rh-clint Rat hepatocyte intrinsic clearance 88.920 uL/min/10^6 cells Moderate 0.74
rh-fuinc Rat hepatocyte fraction unbound in incubation 57.930 % Moderate 0.74
rppb Rat plasma protein binding (% unbound) 15.910 % Moderate 0.74
solubility-dd Solubility at pH 7.4 in DMSO 514.044 uM Moderate 0.74

Approvals:

None

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC J01FA12 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS
Macrolides

Related Drugs by ATC class:

J01FA Macrolides 13 drugs
azithromycinclarithromycindirithromycinerythromycinflurithromycinjosamycinmiocamycinmydecamycinoleandomycinroxithromycinspiramycintelithromycin show all 13 →

Drug Use | Suggest Off label Use Form| |View source of the data|

None




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 12.8 acidic
pKa2 13.95 acidic
pKa3 7.88 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
D01897 KEGG_DRUG
C0073560 UMLSCUI
CHEBI:32103 CHEBI
CHEMBL1908350 ChEMBL_ID
DB13409 DRUGBANK_ID
C033383 MESH_SUPPLEMENTAL_RECORD_UI
12879 IUPHAR_LIGAND_ID
5681 INN_ID
ZPT03UEM0E UNII
5282211 PUBCHEM_CID
010977 NDDF

Pharmaceutical products:

None